257 related articles for article (PubMed ID: 35870472)
21. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study.
Jabbour E; Short NJ; Ravandi F; Huang X; Daver N; DiNardo CD; Konopleva M; Pemmaraju N; Wierda W; Garcia-Manero G; Sasaki K; Cortes J; Garris R; Khoury JD; Jorgensen J; Jain N; Alvarez J; O'Brien S; Kantarjian H
Lancet Haematol; 2018 Dec; 5(12):e618-e627. PubMed ID: 30501869
[TBL] [Abstract][Full Text] [Related]
22. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
23. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
24. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.
Jabbour E; Short NJ; Jain N; Thompson PA; Kadia TM; Ferrajoli A; Huang X; Yilmaz M; Alvarado Y; Patel KP; Garcia-Manero G; Macaron W; Garris R; Konopleva M; Ravandi F; Kantarjian H
Lancet Haematol; 2022 Dec; 9(12):e878-e885. PubMed ID: 36279879
[TBL] [Abstract][Full Text] [Related]
25. Addition of four doses of rituximab to standard induction chemotherapy in adult patients with precursor B-cell acute lymphoblastic leukaemia (UKALL14): a phase 3, multicentre, randomised controlled trial.
Marks DI; Kirkwood AA; Rowntree CJ; Aguiar M; Bailey KE; Beaton B; Cahalin P; Castleton AZ; Clifton-Hadley L; Copland M; Goldstone AH; Kelly R; Lawrie E; Lee S; McMillan AK; McMullin MF; Menne TF; Mitchell RJ; Moorman AV; Patel B; Patrick P; Smith P; Taussig D; Yallop D; Alapi KZ; Fielding AK
Lancet Haematol; 2022 Apr; 9(4):e262-e275. PubMed ID: 35358441
[TBL] [Abstract][Full Text] [Related]
26. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.
Lee DW; Kochenderfer JN; Stetler-Stevenson M; Cui YK; Delbrook C; Feldman SA; Fry TJ; Orentas R; Sabatino M; Shah NN; Steinberg SM; Stroncek D; Tschernia N; Yuan C; Zhang H; Zhang L; Rosenberg SA; Wayne AS; Mackall CL
Lancet; 2015 Feb; 385(9967):517-528. PubMed ID: 25319501
[TBL] [Abstract][Full Text] [Related]
27. Health care utilisation and costs associated with different treatment protocols for newly diagnosed childhood acute lymphoblastic leukaemia: A population-based study in Ontario, Canada.
Gupta S; Sutradhar R; Li Q; Athale U; Bassal M; Breakey V; Gibson PJ; Patel S; Silva M; Zabih V; Pechlivanoglou P; Pole JD; Mittmann N
Eur J Cancer; 2021 Jul; 151():126-135. PubMed ID: 33979728
[TBL] [Abstract][Full Text] [Related]
28. Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial.
Kadia TM; Reville PK; Borthakur G; Yilmaz M; Kornblau S; Alvarado Y; Dinardo CD; Daver N; Jain N; Pemmaraju N; Short N; Wang SA; Tidwell RSS; Islam R; Konopleva M; Garcia-Manero G; Ravandi F; Kantarjian HM
Lancet Haematol; 2021 Aug; 8(8):e552-e561. PubMed ID: 34329576
[TBL] [Abstract][Full Text] [Related]
29. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
Cortes J; Perl AE; Döhner H; Kantarjian H; Martinelli G; Kovacsovics T; Rousselot P; Steffen B; Dombret H; Estey E; Strickland S; Altman JK; Baldus CD; Burnett A; Krämer A; Russell N; Shah NP; Smith CC; Wang ES; Ifrah N; Gammon G; Trone D; Lazzaretto D; Levis M
Lancet Oncol; 2018 Jul; 19(7):889-903. PubMed ID: 29859851
[TBL] [Abstract][Full Text] [Related]
30. Replacing cyclophosphamide/cytarabine/mercaptopurine with cyclophosphamide/etoposide during consolidation/delayed intensification does not improve outcome for pediatric B-cell acute lymphoblastic leukemia: a report from the COG.
Burke MJ; Salzer WL; Devidas M; Dai Y; Gore L; Hilden JM; Larsen E; Rabin KR; Zweidler-McKay PA; Borowitz MJ; Wood B; Heerema NA; Carroll AJ; Winick N; Carroll WL; Raetz EA; Loh ML; Hunger SP
Haematologica; 2019 May; 104(5):986-992. PubMed ID: 30545921
[TBL] [Abstract][Full Text] [Related]
31. Automated Ascertainment of Typhlitis From the Electronic Health Record.
Miller TP; Li Y; Masino AJ; Vallee E; Burrows E; Ramos M; Alonzo TA; Gerbing R; Castellino SM; Hawkins DS; Lash TL; Aplenc R; Grundmeier RW
JCO Clin Cancer Inform; 2022 Sep; 6():e2200081. PubMed ID: 36198128
[TBL] [Abstract][Full Text] [Related]
32. Proteasome subunit expression analysis and chemosensitivity in relapsed paediatric acute leukaemia patients receiving bortezomib-containing chemotherapy.
Niewerth D; Kaspers GJ; Jansen G; van Meerloo J; Zweegman S; Jenkins G; Whitlock JA; Hunger SP; Lu X; Alonzo TA; van de Ven PM; Horton TM; Cloos J
J Hematol Oncol; 2016 Sep; 9(1):82. PubMed ID: 27599459
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of paediatric patients with B-cell acute lymphocytic leukaemia with ABL-class fusion in the pre-tyrosine-kinase inhibitor era: a multicentre, retrospective, cohort study.
den Boer ML; Cario G; Moorman AV; Boer JM; de Groot-Kruseman HA; Fiocco M; Escherich G; Imamura T; Yeoh A; Sutton R; Dalla-Pozza L; Kiyokawa N; Schrappe M; Roberts KG; Mullighan CG; Hunger SP; Vora A; Attarbaschi A; Zaliova M; Elitzur S; Cazzaniga G; Biondi A; Loh ML; Pieters R;
Lancet Haematol; 2021 Jan; 8(1):e55-e66. PubMed ID: 33357483
[TBL] [Abstract][Full Text] [Related]
34. Risk of late effects of treatment in children newly diagnosed with standard-risk acute lymphoblastic leukaemia: a report from the Childhood Cancer Survivor Study cohort.
Essig S; Li Q; Chen Y; Hitzler J; Leisenring W; Greenberg M; Sklar C; Hudson MM; Armstrong GT; Krull KR; Neglia JP; Oeffinger KC; Robison LL; Kuehni CE; Yasui Y; Nathan PC
Lancet Oncol; 2014 Jul; 15(8):841-51. PubMed ID: 24954778
[TBL] [Abstract][Full Text] [Related]
35. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.
Nachman JB; La MK; Hunger SP; Heerema NA; Gaynon PS; Hastings C; Mattano LA; Sather H; Devidas M; Freyer DR; Steinherz PG; Seibel NL
J Clin Oncol; 2009 Nov; 27(31):5189-94. PubMed ID: 19805689
[TBL] [Abstract][Full Text] [Related]
36. Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (≥200 × 10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Group.
Hastings C; Gaynon PS; Nachman JB; Sather HN; Lu X; Devidas M; Seibel NL
Br J Haematol; 2015 Feb; 168(4):533-46. PubMed ID: 25308804
[TBL] [Abstract][Full Text] [Related]
37. Outcomes of intensification of induction chemotherapy for children with high-risk acute myeloid leukemia: A report from the Children's Oncology Group.
Elgarten CW; Wood AC; Li Y; Alonzo TA; Brodersen LE; Gerbing RB; Getz KD; Huang YV; Loken M; Meshinchi S; Pollard JA; Sung L; Woods WG; Kolb EA; Gamis AS; Aplenc R
Pediatr Blood Cancer; 2021 Dec; 68(12):e29281. PubMed ID: 34596937
[TBL] [Abstract][Full Text] [Related]
38. Venetoclax plus 3 + 7 daunorubicin and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial.
Wang H; Mao L; Yang M; Qian P; Lu H; Tong H; Xie W; Zhou D; Huang X; Wang Y; Xu G; Lu Y; Wei J; Mai W; Ye X; Meng H; Shen Y; Huang J; Yu W; Sun J; Sheng J; Yan X; Jin J; Zhu HH
Lancet Haematol; 2022 Jun; 9(6):e415-e424. PubMed ID: 35512726
[TBL] [Abstract][Full Text] [Related]
39. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
40. Predictors of hepatotoxicity and pancreatitis in children and adolescents with acute lymphoblastic leukemia treated according to contemporary regimens.
Denton CC; Rawlins YA; Oberley MJ; Bhojwani D; Orgel E
Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29218844
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]